Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC Sponsored ADR ( (HLN) ) has issued an update.
On September 10, 2025, Haleon PLC announced a notification and public disclosure regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs) under the UK Market Abuse Regulation. The transactions involved the acquisition of Partnership Shares and the award of Matching Shares under the company’s Share Reward Plan by Adrian Morris, General Counsel, and Tamara Rogers, Chief Marketing Officer, on September 9, 2025, at the London Stock Exchange. This disclosure highlights Haleon’s commitment to transparency and regulatory compliance, potentially impacting stakeholder confidence and market perception.
The most recent analyst rating on (HLN) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
Haleon PLC’s overall stock score reflects a strong financial foundation with robust cash flow and profitability margins. However, the lack of revenue growth and challenges in the North American market weigh on the score. Technical indicators and valuation suggest a stable but limited growth outlook, while the earnings call provides some optimism for international performance and operational improvements.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers a diverse range of products across six major categories, including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are founded on trusted science and innovation.
Average Trading Volume: 11,224,080
Technical Sentiment Signal: Buy
Current Market Cap: $43.46B
See more insights into HLN stock on TipRanks’ Stock Analysis page.